U.S. Airlines Stock News

NasdaqGS:RGEN
NasdaqGS:RGENLife Sciences

How Investors Are Reacting To Repligen (RGEN) Earnings Beat Paired With Cautious 2026 Guidance

In February 2026, Repligen Corporation reported that fourth-quarter 2025 revenue rose to US$197.91 million from US$167.55 million a year earlier, swinging from a net loss to net income of US$13.29 million and turning prior per-share losses into positive earnings. Alongside this stronger profitability, the company issued relatively cautious 2026 guidance for revenue of US$810 million to US$840 million and diluted earnings per share of US$1.93 to US$2.01, which contrasted with its recent...
NasdaqGS:IDXX
NasdaqGS:IDXXMedical Equipment

Idexx Board Changes Prompt Fresh Look At Growth Valuation And Risk

IDEXX Laboratories (NasdaqGS:IDXX) announced the upcoming retirement of long-serving Board member M. Anne Szostak. The company also disclosed the appointment of Michael G. Erickson, PhD, to its Board of Directors. These Board changes reflect an ongoing refresh of corporate governance and Board composition. IDEXX Laboratories focuses on diagnostic and software solutions for veterinary practices, livestock, poultry, and water testing, placing the company at the center of long term trends in...
NasdaqGS:BILI
NasdaqGS:BILIInteractive Media and Services

Is It Time To Reassess Bilibili (NasdaqGS:BILI) After Recent Share Price Volatility?

If you are wondering whether Bilibili’s current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers actually say about value. Bilibili’s stock has been volatile, with a 7 day return of an 8% decline, a 30 day return of a 17.9% decline, but a 1 year return of 37.5% and a 3 year return of 32.0%. This gives mixed signals about how the market is currently pricing the business. Recent headlines around Bilibili have focused on its...
NYSE:ABBV
NYSE:ABBVBiotechs

Does AbbVie (ABBV) Share Price Reflect Its DCF Value Despite High P/E Multiple

If you are wondering whether AbbVie’s current share price lines up with its underlying worth, you are not alone. This article is built to help you unpack that question clearly. AbbVie recently closed at US$224.69, with returns of 0.2% over the last week, 0.3% over the last month, a 2.0% decline year to date, and 13.3% over the past year, alongside longer term returns of 62.2% over 3 years and 157.5% over 5 years. Recent coverage around AbbVie has focused on its position as a large...
NYSE:VVX
NYSE:VVXAerospace & Defense

How Investors May Respond To V2X (VVX) Record 2025 Results And ATSP5 Contract Vehicle Inclusion

V2X, Inc. recently reported its full-year 2025 results, with revenue rising to US$4.48 billion and net income reaching US$77.88 million, alongside earnings guidance for 2026 and a place on the US$25 billion ATSP5 defense technology contract vehicle. Together with record quarterly revenue, major awards such as the T-6 aircraft program, and AI-focused partnerships, these updates underline V2X’s expanding role in high‑complexity defense support and modernization work. We’ll now examine how...
NasdaqGS:PCVX
NasdaqGS:PCVXBiotechs

Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Volatility

Vaxcyte stock overview after recent price move Vaxcyte (PCVX) has drawn fresh attention after its recent share move, with the stock last closing at $60. For investors, the key question is how this price lines up with the company’s current fundamentals. See our latest analysis for Vaxcyte. That latest move to $60 comes after a choppy stretch, with a 1 day share price return of a 4.82% decline but a 90 day share price return of 20.94%, while the 1 year total shareholder return sits at a 19.16%...
NasdaqGS:MSFT
NasdaqGS:MSFTSoftware

Is Microsoft's AI Data Center Splurge Reshaping the Investment Case For Microsoft (MSFT)?

In February 2026, Microsoft’s latest earnings and disclosures showed AI and cloud-driven growth accompanied by sharply higher capital expenditures on data centers and infrastructure, while new partnerships, marketplace listings, and leadership changes in gaming underscored how deeply the company is embedding AI across its ecosystem. An important undercurrent is rising investor debate over whether Microsoft’s very large AI infrastructure outlays, extended depreciation schedules, and reliance...
NYSE:DE
NYSE:DEMachinery

Deere Bayer Data Link Aims To Deepen Precision Farming Ecosystem

John Deere and Bayer are partnering to launch wireless, integrated farm data transfer for U.S. growers. The connection links Bayer's FieldView platform with John Deere's Operations Center to move agronomic prescriptions directly to machines. The capability is planned to be available for the 2026 U.S. season, with global expansion expected after that. For Deere (NYSE:DE), this move adds another piece to its digital agriculture stack at a time when investors are already paying attention to...
NasdaqGS:SIMO
NasdaqGS:SIMOSemiconductor

Is It Too Late To Consider Silicon Motion Technology (SIMO) After 144% One Year Share Price Surge

If you are wondering whether Silicon Motion Technology is offering good value at its current price, you are not alone. The stock has drawn attention from investors trying to work out what a fair price really looks like. The share price closed at US$131.08 recently, with a 0.9% decline over the last 7 days but gains of 12.8% over 30 days, 39.8% year to date, 144.4% over 1 year, 109.4% over 3 years and 154.3% over 5 years. Those moves have kept the company on many investors' watchlists,...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress

AbCellera Biologics (ABCL) has drawn fresh attention after reporting a narrower quarterly loss than anticipated, supported by a substantial patent litigation settlement that lifted liquidity and coincided with progress across its clinical programs and manufacturing build out. See our latest analysis for AbCellera Biologics. The strong 1 day share price return of 12.54% and 7 day share price return of 11.49% around the results suggest investors are reassessing AbCellera’s risks and prospects...
NasdaqGS:DXPE
NasdaqGS:DXPETrade Distributors

DXP Enterprises (DXPE) Margin Gains And EPS Growth Test Bullish Narratives

DXP Enterprises (DXPE) has wrapped up FY 2025 with Q4 revenue of US$527.4 million and basic EPS of US$1.46, alongside net income excluding extraordinary items of US$22.8 million. On a trailing twelve month basis, revenue stands at about US$2.0 billion with EPS of US$5.65 and net income of US$88.6 million. The company has seen quarterly revenue move from US$470.9 million in Q4 2024 to US$527.4 million in Q4 2025, with basic EPS shifting from US$1.36 to US$1.46 over the same period. This puts...
OTCPK:LKNC.Y
OTCPK:LKNC.YHospitality

Luckin Coffee (OTCPK:LKNC.Y) Margin Compression Tests Bullish Growth Narrative After FY 2025 Results

Luckin Coffee (OTCPK:LKNC.Y) has wrapped up FY 2025 with fourth quarter revenue of about C¥12.8b and basic EPS of C¥1.62, rounding out a year in which trailing twelve month revenue reached roughly C¥49.3b and EPS came in at about C¥11.23. The company has seen quarterly revenue move from roughly C¥9.6b in Q4 2024 to C¥12.8b in Q4 2025, while basic EPS shifted from C¥2.64 to C¥1.62 over the same period, setting up a mixed picture that investors will likely weigh against the reported net income...
OTCPK:FMCC
OTCPK:FMCCDiversified Financial

Do Sub‑6% Mortgage Rates Reshape Freddie Mac's Competitive Moat and Risk Profile (FMCC)?

Earlier this week, Freddie Mac reported that the average 30-year fixed-rate mortgage fell to 5.98%, dropping below the 6% threshold for the first time since 2022. This move, paired with improving home availability, highlights how shifts in borrowing costs can quickly influence expectations for spring housing activity and mortgage demand. With mortgage rates dipping below 6%, we will explore how this development shapes Federal Home Loan Mortgage’s investment narrative and market...
NYSE:ASPN
NYSE:ASPNChemicals

Why Aspen Aerogels (ASPN) Is Down 13.3% After Impairment-Driven Loss And Strategic Review News

In February 2026, Aspen Aerogels reported fourth-quarter 2025 sales of US$41.34 million versus US$123.09 million a year earlier, swung to a net loss of US$72.91 million, recorded an impairment charge on property, plant and equipment, and launched a broad review of options for its business and capital structure. An important insight is that management characterizes this strategic review as coming from a position of financial strength and operational progress, even as the company posts a...
NasdaqGS:KHC
NasdaqGS:KHCFood

A Look At Kraft Heinz (KHC) Valuation As Breakup Plan Pauses And New Leadership Refocuses The Business

Leadership reset and renewed single company focus Kraft Heinz (KHC) has put its breakup plan on hold and is instead regrouping under new leadership, with fresh capital earmarked for marketing, sales, R&D, and product quality in its core U.S. business. See our latest analysis for Kraft Heinz. Recent announcements on leadership changes and the paused breakup have come after a mixed stretch for investors, with a 1 year total shareholder return decline of 15% and a 3 year total shareholder return...
NYSE:WM
NYSE:WMCommercial Services

How Investors Are Reacting To Waste Management (WM) Opening Its New AI-Powered Flagship Recycling Facility

Waste Management recently opened a US$90 million AI-powered recycling facility in Pembroke Pines, Florida, capable of processing up to 275,000 tons of recyclables annually as part of its US$1.40 billion national upgrade program. As one of the largest and highest-volume recycling plants in the United States, this facility underscores Waste Management’s push to combine advanced technology with expanded environmental services, including public education efforts to lift local recycling...
NYSE:LB
NYSE:LBReal Estate

LandBridge (LB) Margin Jump To 15.1% Tests Justification For Premium P/E Multiple

LandBridge (LB) just wrapped up FY 2025 with fourth quarter revenue of US$56.8 million and basic EPS of US$0.29, while trailing twelve month EPS came in at US$1.08 on revenue of US$199.1 million, setting a clear reference point for how the business is currently earning its profits. The company has seen revenue move from US$36.5 million in Q4 2024 to US$56.8 million in Q4 2025, with quarterly EPS shifting from US$0.12 to US$0.29 over the same stretch. Those figures sit alongside trailing...
NYSE:EG
NYSE:EGInsurance

How Everest Group’s US$2 Dividend Plan At Everest Group (EG) Has Changed Its Investment Story

Everest Group, Ltd. previously announced that its Board of Directors declared a US$2.00 per common share dividend, payable on or before March 27, 2026 to shareholders of record as of March 13, 2026. This dividend affirmation highlights Everest Group’s ongoing commitment to returning cash to investors while it continues operating as a global provider of property, casualty, and specialty reinsurance and insurance solutions. We’ll now examine how this US$2.00 per share cash return fits into...
NasdaqGS:CENX
NasdaqGS:CENXMetals and Mining

Century Aluminum (CENX) Valuation Check After Strong Multi Year Share Price And Return Performance

Century Aluminum stock moves after strong multi year return profile Century Aluminum (CENX) has drawn fresh attention as its shares reflect a very large 3 year total return and a 1 year total return of 170%. This has raised questions about how its recent performance lines up with current fundamentals. See our latest analysis for Century Aluminum. The share price is now US$52.21. While there has been a 1 day share price decline of 1.5%, the 3 month share price return of 74.2% sits alongside a...
NYSE:KMX
NYSE:KMXSpecialty Retail

Is CarMax (KMX) Offering An Opportunity After A 1 Year 47% Share Price Decline

If you are wondering whether CarMax shares still offer value after a rough stretch, you are not alone. This article is designed to help you weigh what the current price might really reflect. The stock recently closed at US$42.86, with returns of a 3.9% decline over 7 days, a 7.5% decline over 30 days, a 9.1% gain year to date, and a 47.7% decline over 1 year that may have shifted how the market views its risk and potential. These moves come as investors continue to reassess large used car...
NYSEAM:CET
NYSEAM:CETCapital Markets

Did Central Securities' (CET) 2025 Net Income Reveal a Shift in Its Investment Narrative?

Central Securities Corporation (NYSE American: CET) has released its annual report for the year ended December 31, 2025, reporting full-year net income of US$265.21 million. The annual report gives investors a clearer view into how this closed-end investment company managed its portfolio and operations over the 2025 calendar year. We will now examine how Central Securities’ 2025 net income performance shapes the company’s investment narrative for shareholders and prospective...
NasdaqGS:NVDA
NasdaqGS:NVDASemiconductor

Nvidia (NVDA) Margins Near 56% Reinforce Bullish AI Narrative Despite Cash Quality Doubts

Nvidia (NVDA) has put up big headline numbers for FY 2026, with fourth quarter revenue of about US$68.1b and basic EPS of US$1.77, capping a year in which trailing 12 month EPS reached US$4.93 alongside revenue of roughly US$215.9b. Over the past six quarters, the company has seen quarterly revenue move from about US$35.1b with EPS of US$0.79 in FY 2025 Q3 to US$68.1b and EPS of US$1.77 in FY 2026 Q4. This sets up a story where investors are watching how rich margins and strong earnings...
NasdaqGS:SHEN
NasdaqGS:SHENTelecom

Shenandoah Telecommunications (SHEN) Q4 Loss Highlights Ongoing Profitability Strain Versus Bullish Fiber Narratives

Shenandoah Telecommunications (SHEN) closed out FY 2025 with Q4 revenue of US$91.6 million and a basic EPS loss of US$0.13, as net income excluding extra items came in at a loss of US$7.3 million. The company reported quarterly revenue of US$85.4 million in Q4 2024 and US$91.6 million in Q4 2025, while basic EPS remained negative over that stretch, ranging from a loss of US$0.15 to US$0.20 per quarter. For investors, the latest results keep the focus on margins and the path back toward more...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

Evaluating IDEAYA Biosciences (IDYA) Valuation As Recent Volatility Sends Mixed Signals

What IDEAYA Biosciences Stock Is Telling Investors Right Now IDEAYA Biosciences (IDYA) has drawn attention after a mixed run, with a 1 day gain of 0.7% contrasting with declines over the past month and past 3 months, prompting closer scrutiny of its setup. See our latest analysis for IDEAYA Biosciences. At around $31.90, IDEAYA Biosciences has seen near term pressure, with a 30 day share price return of a 5.2% decline and a 90 day share price return of a 10.4% decline, while its 1 year total...